Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab191918-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$59.90
|
|
|
Ab191918-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$259.90
|
|
|
Ab191918-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$669.90
|
|
|
Ab191918-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,069.90
|
|
Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG4SP; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | Quisovalimab (anti-TNFSF14) - Primary antibody, specific to TNFSF14, Human IgG4SP |
|---|---|
| Synonyms | CD 258 antibody | CD258 antibody | CD258 antigen antibody | Delta transmembrane LIGHT antibody | Herpes virus entry mediator ligand antibody | SAR252067 | Herpesvirus entry mediator A antibody | Herpesvirus entry mediator ligand antibody | herpesvirus ent |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Cytokine that binds to TNFRSF3/LTBR. Binding to the decoy receptor TNFRSF6B modulates its effects. Activates NFKB, stimulates the proliferation of T-cells, and inhibits growth of the adenocarcinoma HT-29. Acts as a receptor for Herpes simplex virus. Post |
| Host species | Human |
| Specificity | TNFSF14 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Quisovalimab (anti-TNFSF14) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab (anti-TNFSF14) can be used in COVID-19 acute respiratory distress syndrome and other studies. |
| Isotype | Human IgG4SP |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 2427667-03-4 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Quisovalimab (anti-TNFSF14) (Ab191918) - ELISA
Immobilized Recombinant Human N-6His-TEV-LIGHT-ECD (83-240 aa) protein at 2.0 μg/mL can bind Quisovalimab (anti-TNFSF14) (Ab191918) with the EC50 of 25.18 ng/mL.
Quisovalimab (anti-TNFSF14) (Ab191918) - SEC
The purity of Quisovalimab (anti-TNFSF14) (Ab191918) is more than 95% verified by HPLC.